MINNEAPOLIS--(BUSINESS WIRE)--Demonstrating its dedication to close the loop for diabetes management, Medtronic, Inc. (NYSE:MDT) today announced that the first patient has been enrolled as part of the ASPIRE study of the MiniMed Paradigm x54 System featuring Low Glucose Suspend automation. Low Glucose Suspend works by automatically suspending insulin delivery temporarily if blood glucose levels become too low as defined by the patient and his or her healthcare provider and is a feature available commercially in Medtronic’s Paradigm® Veo™ System in more than 35 countries outside of United States.
